iShares Micro-Cap
Latest iShares Micro-Cap News and Updates
What Do Analysts Expect from Flotek’s 4Q16 Earnings?
In 4Q16, analysts expect Flotek Industries (FTK) to post an adjusted loss per share of ~$0.04.
Wall Street Analysts’ Forecasts for Flotek Industries
On May 3, 2017, after Flotek Industries’ 1Q17 earnings were released, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.”
How Flotek Could React to Upstream Operators’ Capex and the Rig Count
From 1Q16 to 1Q17, Flotek’s EBITDA margin shrank to 3.3% from 4.1%. FTK’s EBITDA margin has been 1.7%, on average, for the past five quarters.
What Analysts Expect from Flotek Industries’ 3Q17 Earnings
In 3Q17, analysts expect Flotek Industries (FTK) to report adjusted earnings per share of $0.02. Wall Street expects FTK’s revenues to rise 1% over 2Q17 to $86.2 million.
Best Oilfield Services Stocks for 1Q17 by EPS Growth
Among our group of OFS companies, analysts expect Halliburton (HAL) to see the highest rise in adjusted EPS in 1Q17.
How Rig Count and Upstream Operator Capex Affected FTK
From 2Q16 to 2Q17, Flotek Industries’ (FTK) EBITDA margin (or EBITDA as a percentage of revenues) improved to 2.3% from 0.7%.
Ignyta’s Drug Pipeline
Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.
A Closer Look at Insys Therapeutics’ Performance Year-to-Date
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
Analysts’ Recommendations for Cara Therapeutics in January 2018
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.
Inside Atara Biotherapeutics’ Promising Product Pipeline
Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.
A Look at Short Interest in Flotek Industries on October 16
Short interest in Flotek Industries (FTK) as a percentage of its float was 20.3% on October 16, 2017, compared to 22.8% on June 30, 2017.
Basic Energy Services’ Next-7-Day Stock Price Forecast
Since 2Q17 earnings were announced on July 27, Basic Energy Services’ implied volatility (or IV) has risen from 62% to the current level.
Wall Street Analysts’ Recommendations for Flotek Industries
On August 10, 2017, all of the sell-side analysts tracking Flotek Industries rated it as a “buy.” None of the analysts rated Flotek as a “hold” or “sell.”
How Flotek Industries’ 2017 Capex Plans Changed
Flotek Industries’ (FTK) cash from operating activities (or CFO) remained negative in 2Q17, continuing with a negative cash flow trend in 1Q17.
Inside Flotek Industries’ New 2017 Capex Plan
Flotek’s (FTK) CFO (cash from operating activities) was negative in 1Q17, after being positive for three quarters. FTK’s CFO was -$2.5 million in 1Q17.
What Was the Short Interest in Basic Energy Services on May 8?
Short interest in Basic Energy Services (BAS) as a percentage of its float is 4.4% as of May 8 compared to 4.6% as of March 31, 2017.
Can Basic Energy Grow after Emerging from Bankruptcy?
On October 25, 2016, Basic Energy Services (BAS) filed for bankruptcy after a persistently weak performance in an energy market that was gripped by pricing weakness.
Analyzing Basic Energy Services’ Future Drivers
Basic Energy Services’ (BAS) management expects increased rig utilization and better pricing to result in a higher operating margin in 1Q17.
Flotek Industries’ Capex: Impact of a Credit Facility Agreement
In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flows trended over the past few quarters.
What Are Wall Street’s Forecasts for Flotek before 4Q16 Earnings?
On January 13, all the analysts tracking Flotek Industries rated it a “buy” or some equivalent.
Will Upstream Operators’ Capex Impact Tidewater’s Margin?
In the past few years, some major US upstream and integrated companies reduced their capex following the sharp fall in crude oil prices.
What Are Tidewater’s Growth Drivers?
From April 1 to September 30 of fiscal 2017, Tidewater’s (TDW) revenues fell 46% compared to the same period in fiscal 2016.
What Does Flotek Industries’ Implied Volatility Suggest?
On January 13, 2017, Flotek Industries (FTK) had an implied volatility of 81%.
Will Upstream Operators’ Capex Affect Flotek’s 4Q16 Margin?
In the past couple of years, some of the major US upstream and integrated companies have reduced capital expenditure as a result of crude oil’s sharp decline.
